Autolus Therapeutics plc

NasdaqGS:AUTL Stock Report

Market Cap: US$1.1b

Autolus Therapeutics Future Growth

Future criteria checks 2/6

Autolus Therapeutics is forecast to grow earnings and revenue by 52.4% and 48% per annum respectively. EPS is expected to grow by 58.7% per annum. Return on equity is forecast to be -43.5% in 3 years.

Key information

52.4%

Earnings growth rate

58.7%

EPS growth rate

Biotechs earnings growth24.8%
Revenue growth rate48.0%
Future return on equity-43.5%
Analyst coverage

Good

Last updated09 Apr 2024

Recent future growth updates

Recent updates

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09
We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12
Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Dec 15
We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Autolus: Developing Better CAR-T In Refractory ALL

Jul 20

Reassessing Autolus Therapeutics

May 04

Will Autolus Therapeutics (NASDAQ:AUTL) Spend Its Cash Wisely?

Apr 28
Will Autolus Therapeutics (NASDAQ:AUTL) Spend Its Cash Wisely?

Do Insiders Own Lots Of Shares In Autolus Therapeutics plc (NASDAQ:AUTL)?

Feb 16
Do Insiders Own Lots Of Shares In Autolus Therapeutics plc (NASDAQ:AUTL)?

Earnings and Revenue Growth Forecasts

NasdaqGS:AUTL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026187-601344
12/31/202572-127-73-1019
12/31/202430-174-102-1289
12/31/20232-208-157-146N/A
9/30/20236-158-145-135N/A
6/30/20237-155-142-127N/A
3/31/20237-152-133-120N/A
12/31/20226-149-123-112N/A
9/30/20223-164-119-107N/A
6/30/20221-155-119-110N/A
3/31/20222-146-123-116N/A
12/31/20212-142-127-118N/A
9/30/20213-143-149-136N/A
6/30/20213-147-154-141N/A
3/31/20212-145-145-131N/A
12/31/20202-142-132-118N/A
9/30/20202-140-134-123N/A
6/30/20201-130-120-109N/A
3/31/20201-127-113-99N/A
12/31/20193-124-120-101N/A
9/30/20193-104-109-88N/A
6/30/20193-89-93-72N/A
3/31/20193-68-76-61N/A
12/31/20181-58-56-43N/A
9/30/20181-45-41-32N/A
6/30/20181-41N/AN/AN/A
3/31/20182-38N/AN/AN/A
12/31/20172-29N/AN/AN/A
9/30/20172-20N/A-16N/A
9/30/20161-13N/A-10N/A
9/30/20150-7N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AUTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AUTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AUTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AUTL's revenue (48% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: AUTL's revenue (48% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AUTL is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.